Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Emvision Medical Devices Ltd

Healthcare AU EMV

1.672AUD
-0.038(2.22%)

Last update at 2026-03-11T04:59:00Z

Day Range

1.651.72
LowHigh

52 Week Range

1.632.43
LowHigh

Fundamentals

  • Previous Close 1.71
  • Market Cap159.85M
  • Volume48959
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.40189M
  • Revenue TTM5.43M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM 5.43M
  • Diluted EPS TTM-0.12

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -8.35541M -2.03187M -3.87071M -6.10928M -8.39871M
Minority interest - - - - -
Net income -9.80554M -2.72961M -3.87071M -6.12740M -10.15744M
Selling general administrative 1.80M 1.83M 8.17M 7.42M 6.99M
Selling and marketing expenses 7.34M 6.31M - - -
Gross profit 5.05M 11.22M - - -
Reconciled depreciation 0.41M 0.41M 0.34M 0.24M 0.11M
Ebit -8.84355M -8.76264M -3.83543M -6.09116M -8.38888M
Ebitda -8.71096M -8.35206M -3.49342M -5.84782M -8.27492M
Depreciation and amortization 0.13M 0.41M 0.34M 0.24M 0.11M
Non operating income net other - - - - -
Operating income -8.12886M -1.61441M -3.83543M -6.09116M -8.38888M
Other operating expenses 13.18M 12.83M 10.93M 10.47M 10.18M
Interest expense 0.09M 0.12M 0.04M 0.02M 0.00984M
Tax provision 1.45M 0.70M 0.00000M 0.00000M 0.00000M
Interest income 0.58M 0.34M 0.04M 0.02M 0.05M
Net interest income 0.49M 0.23M 0.08M -0.00248M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.45M 0.70M 7.01M 0.02M 1.76M
Total revenue 5.05M 11.22M 4.59M 2.39M 0.52M
Total operating expenses 13.18M 12.83M 10.93M 10.47M 10.18M
Cost of revenue - 0.41M - - -
Total other income expense net -0.22655M -0.41746M 6.97M -0.01812M -0.00984M
Discontinued operations - - - - -
Net income from continuing ops -9.80554M -2.72961M -3.87071M -6.10928M -8.39871M
Net income applicable to common shares -9.80554M -2.72961M -3.87071M -6.10928M -8.39871M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 15.57M 23.97M 11.52M 8.51M 10.77M
Intangible assets 0.61M - 0.48M 0.48M 0.48M
Earning assets - - - - -
Other current assets 3.19M 0.35M 0.27M 0.07M 0.12M
Total liab 6.29M 5.46M 6.40M 1.43M 0.72M
Total stockholder equity 9.28M 18.52M 5.12M 7.08M 10.05M
Deferred long term liab - - - - -
Other current liab 0.87M 1.01M 2.30M 0.68M 0.48M
Common stock - 41.57M 26.23M 23.21M 21.40M
Capital stock 41.75M - 26.23M 23.21M 21.40M
Retained earnings -34.81621M -26.51575M -25.65886M -21.78815M -15.67887M
Other liab - - 0.05M 0.03M -
Good will - - - - -
Other assets - - - - -
Cash 10.46M 18.60M 9.97M 6.80M 9.69M
Cash and equivalents - - - - -
Total current liabilities 2.84M 3.41M 6.04M 0.85M 0.68M
Current deferred revenue - 1.05M 0.68M -0.19688M -0.16933M
Net debt - -15.70122M -6.92803M -6.06122M -9.47639M
Short term debt - 1.07M 2.73M 0.20M 0.17M
Short long term debt - - 2.50M - -
Short long term debt total - 2.90M 3.04M 0.74M 0.21M
Other stockholder equity - - 4.55M 5.66M 4.33M
Property plant equipment - - 0.80M 0.96M 0.32M
Total current assets 13.94M 21.87M 10.23M 7.07M 9.98M
Long term investments - - - - -
Net tangible assets - - 4.64M 6.60M 9.57M
Short term investments 0.07M - 0.31M 0.18M -
Net receivables - 2.92M - 0.07M 0.12M
Long term debt 2.65M - - - -
Inventory - - - - -
Accounts payable 0.96M 0.29M 0.33M 0.18M 0.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 3.46M 4.55M 5.66M 4.33M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 0.65M -1.28336M -1.43807M -0.79865M
Deferred long term asset charges - - - - -
Non current assets total 1.63M 2.10M 1.28M 1.44M 0.80M
Capital lease obligations 0.88M - 0.54M 0.74M 0.21M
Long term debt total - - 0.31M 0.54M 0.04M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.05037M -0.30241M -0.18729M -0.19112M -0.12725M
Change to liabilities - - 2.36M 0.04M -0.05321M
Total cashflows from investing activities -0.05037M -0.30241M -0.18729M -0.19112M -0.12725M
Net borrowings - - 2.53M -0.17510M -0.09767M
Total cash from financing activities -0.25834M 15.00M 2.52M 1.08M 8.90M
Change to operating activities - - -0.00067M 0.11M -0.09091M
Net income -9.80554M -2.72961M -3.87071M -6.10928M -8.39871M
Change in cash -8.14471M 8.71M 3.17M -2.89048M 5.41M
Begin period cash flow 18.60M 9.89M 6.80M 9.69M 4.28M
End period cash flow 10.46M 18.60M 9.97M 6.80M 9.69M
Total cash from operating activities -7.83600M -5.99171M 0.83M -3.78204M -4.49452M
Issuance of capital stock -0.00238M 15.25M -0.00574M 1.26M 9.00M
Depreciation - 0.41M 0.34M 0.24M 0.11M
Other cashflows from investing activities - -0.18731M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.27359M -0.13640M 0.07M 0.05M 0.05M
Sale purchase of stock -0.00238M 15.25M -0.00574M 1.26M 9.00M
Other cashflows from financing activities 0.00000M -0.24447M 2.75M -0.19112M -0.12725M
Change to netincome - - 1.93M 1.89M 3.93M
Capital expenditures 0.05M 0.30M 0.19M 0.19M 0.13M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.91M -4.65050M 0.07M 0.05M 1.33M
Stock based compensation - 0.87M 1.91M 1.88M 3.93M
Other non cash items -8.74932M 1.39M 4.36M 2.09M -0.13864M
Free cash flow -7.88637M -6.29412M 0.65M -3.97316M -4.62177M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
EMV
Emvision Medical Devices Ltd		 -0.038 2.22% 1.67 - - 29.45 8.12 -21.5294
COH
Cochlear Ltd		 0.89 0.49% 183.41 35.04 28.33 5.17 6.50 5.41 22.39
4DX
4DMEDICAL Ltd		 -0.05 1.13% 4.38 - - 421.18 37.59 411.50 -7.2899
AVR
Anteris Technologies Global Corp		 0.27 3.14% 8.86 - - 495.24 162.25 283.45 -5.1986
PNV
Polynovo Ltd		 0.05 5.56% 0.95 92.50 30.40 4.58 7.52 4.45 89.43

Reports Covered

Stock Research & News

View All

Profile

EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non-invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia.

Emvision Medical Devices Ltd

65 Epping Road, Macquarie Park, NSW, Australia, 2113

Key Executives

Name Title Year Born
Dr. Ronald Peter Weinberger AIMM, BSc (Hons), Ph.D. CEO, MD & Director NA
Mr. Scott Kirkland Exec. Director NA
Ms. Emma Waldon CFO & Company Sec. 1976
Dr. Konstanty Bialkowski Head of Technology Devel. NA
Prof. Stuart Crozier B.E., M.Sc., Ph.D. Chairman of Clinical Advisory Board & Chief Scientific Officer NA
Mr. Robert Tiller Head of Design NA
Ms. Forough Khandan Head of New Product Devel. NA
Dr. Merricc Edgar-Hughes Ph.D. Head of Quality & Regulatory Affairs NA
Dr. Konstanty Bialkowski Head of Tech Development NA
Mr. Scott Kirkland CEO, MD & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.